List of publications using AZD 2281 (Axon 1464) purchased from Axon Medchem

(Total 28 publication citations listed; updated AUGUST 2017) 

2017
Knittel, G., Rehkämper, T., Korovkina, D., Liedgens, P., Fritz, C., Torgovnick, A., ... & Riabinska, A. (2017). Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia. Nature Communications, 8, 153.
 
Schmitt, A., Knittel, G., Welcker, D., Yang, T. P., George, J., Nowak, M., ... & Reinhardt, H. C. (2017). ATM Deficiency Is Associated with Sensitivity to PARP1-and ATR Inhibitors in Lung Adenocarcinoma. Cancer Research, 77(11), 3040-3056.
 
Schoonen, P. M., Talens, F., Stok, C., Gogola, E., Heijink, A. M., Bouwman, P., ... & Rottenberg, S. (2017). Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells. Nature Communications, 8, 15981.
(* Olaparib, MK-1775, or MK4827 are all from Axon Medchem.)
 
Perkhofer, L., Schmitt, A., Carrasco, M. C. R., Ihle, M., Hampp, S., Ruess, D. A., ... & Lin, Q. (2017). ATM deficiency generating genomic instability sensitizes pancreatic ductal adenocarcinoma cells to therapy-induced DNA damage. Cancer Research, canres-0634.
 
Muster, B., Rapp, A., & Cardoso, M. C. (2017). Systematic analysis of DNA damage induction and DNA repair pathway activation by continuous wave visible light laser micro-irradiation. AIMS GENETICS, 4(1), 47-68.
 
Guo, Z. P., Hu, Y. C., Xie, Y., Jin, F., Song, Z. Q., Liu, X. D., ... & Zhou, P. K. (2017). MLN4924 suppresses the BRCA1 complex and synergizes with PARP inhibition in NSCLC cells. Biochemical and biophysical research communications, 483(1), 223-229.
 
2016 
Vaclová, T., Woods, N. T., Megías, D., Gomez-Lopez, S., Setién, F., García Bueno, J. M., ... & Monteiro, A. N. (2016). Germline missense pathogenic variants in the BRCA1 BRCT domain, p. Gly1706Glu and p. Ala1708Glu, increase cellular sensitivity to PARP inhibitor olaparib by a dominant negative effect. Human molecular genetics, 25(24), 5287-5299.
 
Sosna, J., Philipp, S., Chico, J. F., Saggau, C., Fritsch, J., Föll, A., ... & Trauzold, A. (2016). Differences and similarities in TRAIL-and tumor necrosis factor-mediated necroptotic signaling in cancer cells. Molecular and cellular biology, 36(20), 2626-2644.
 
Ratner, Elena S., et al. "Triapine potentiates platinum-based combination therapy by disruption of homologous recombination repair." British journal of cancer 114.7 (2016): 777-786.

2015
Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells. Journal of cellular biochemistry.
Węsierska‐Gądek, J., Mauritz, M., Mitulovic, G., & Cupo, M.
J.Cell.Biochem. 2015, epub ahead of print
*A set of PARP-1 inhibitors (NU1025, AZD2461, iniparib, olaparib and rucaparib) were obtained from Axon Medchem.

A Systematic Analysis of Factors Localized to Damaged Chromatin Reveals PARP-Dependent Recruitment of Transcription Factors.
Izhar, L., Adamson, B., Ciccia, A., Lewis, J., Pontano-Vaites, L., Leng, Y., ... & Elledge, S. J.
Cell Rep. 2015 Jun 9;11(9):1486-500. doi: 10.1016/j.celrep.2015.04.053. Epub 2015 May 21. 

2014
APC/CCdh1 controls CtIP stability during the cell cycle and in response to DNA damage.
Lafranchi, L., De Boer, H. R., De Vries, E. G., Ong, S. E., Sartori, A. A., & Van Vugt, M. A.
EMBO J. 2014 Dec 1;33(23):2860-79. doi: 10.15252/embj.201489017. Epub 2014 Oct 27.
*Olaparib and RO3306 from Axon Medchem

TNF-induced necroptosis and PARP-1-mediated necrosis represent distinct routes to programmed necrotic cell death.
Sosna, J., Voigt, S., Mathieu, S., Lange, A., Thon, L., Davarnia, P., ... & Adam, D. (2014).
Cell Mol Life Sci. 2014 Jan;71(2):331-48. doi: 10.1007/s00018-013-1381-6. Epub 2013 Jun 13.

Triapine Disrupts CtIP-mediated Homologous Recombination Repair and Sensitizes Ovarian Cancer Cells to PARP and Topoisomerase Inhibitors.
Lin, Z. P., Ratner, E. S., Whicker, M. E., Lee, Y., & Sartorelli, A. C.
Mol Cancer Res. 2014 Mar;12(3):381-93. doi: 10.1158/1541-7786.MCR-13-0480. Epub 2014 Jan 10.

2013
Systematic Screen Identifies miRNAs That Target RAD51 and RAD51D to Enhance Chemosensitivity.
Huang, J. W., Wang, Y., Dhillon, K. K., Calses, P., Villegas, E., Mitchell, P. S., Muneesh T., Kemp C.J. & Taniguchi, T.
Mol Cancer Res. 2013 Dec;11(12):1564-73. doi: 10.1158/1541-7786.MCR-13-0292. Epub 2013 Oct 2.

Targeted Radiosensitization of ETS Fusion–Positive Prostate Cancer through PARP1 Inhibition.
S Han, JC Brenner, A Sabolch, W Jackson, C Speers, K Wilder-Romans,KE Knudsen, TS Lawrence, AM Chinnaiyan, and FY. Feng.
Neoplasia. 2013 Oct;15(10):1207-17.

PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells.
L Booth, N Cruickshanks, T Ridder, Y Dai, S Grant and P Dent.
Cancer Biol Ther. 2013 May;14(5):458-65. doi: 10.4161/cbt.24424.

2012
Plk1 and CK2 Act in Concert to Regulate Rad51 during DNA Double Strand Break Repair.
K Yata, J Lloyd, S Maslen, JY Bleuyard, M Skehel, SJ Smerdon, F Esashi.
Mol Cell. 2012 Feb 10;45(3):371-83. doi: 10.1016/j.molcel.2011.12.028.

MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition.
Y Wang, JW Huang, P Calses, CJ Kemp, T Taniguchi.
Cancer Res. 2012 Aug 15;72(16):4037-46. doi: 10.1158/0008-5472.CAN-12-0103. Epub 2012 Jul 3.

Poly(ADP-ribose) Polymerase 1 Modulates the Lethality of CHK1 Inhibitors in Mammary Tumors.
Y Tang, HA Hamed, A Poklepovic, Y Dai, S Grant, P Dent.
Mol Pharmacol. 2012 Aug;82(2):322-32. doi: 10.1124/mol.112.078907. Epub 2012 May 17.

PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma.
JC Brenner, FY Feng, S Han, S Patel, SV Goyal, LM Bou-Maroun, M Liu, R Lonigro, JR Prensner, SA Tomlins, AM Chinnaiyan.
Cancer Res. 2012 Apr 1;72(7):1608-13. doi: 10.1158/0008-5472.CAN-11-3648. Epub 2012 Jan 27.

Therapeutic Targeting of ETS Rearranged Cancers.
JC Brenner, 2012 
PhD dissertation. University of Michigan. 

2011
PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer.
I Paul, KI Savage, JK Blayney, E Lamers, K Gately, K Kerr, M Sheaff, K Arthur, DJ Richard, PW Hamilton, JA James, KJ O'Byrne, DP Harkin, JE Quinn, DA Fennell.
J Pathol. 2011 Aug;224(4):564-74. doi: 10.1002/path.2925. Epub 2011 Jun 27.

PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation.
DG van Vuurden, E Hulleman, OLM Meijer, LE Wedekind, M Kool, H Witt, PWP Vandertop, T Würdinger, DP Noske, GJL Kaspers, J Cloos.
Oncotarget. 2011 Dec;2(12):984-96.

MicroRNA-138 Modulates DNA Damage Response by Repressing Histone H2AX Expression.
Y Wang, JW Huang, M Li, WK Cavenee, PS Mitchell, X Zhou, M Tewari, FB Furnari, T Taniguchi.
Mol Cancer Res. 2011 Aug;9(8):1100-11. doi: 10.1158/1541-7786.MCR-11-0007. Epub 2011 Jun 21.

PARP Inhibitors Synergize With Loss of Checkpoint Control to Kill Mammary Carcinoma Cells.
P Dent, Y Tang - 2011
DTIC Document [online]

Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1.
S Vance, E Liu, L Zhao, JD Parsels, LA Parsels, JL Brown, J Maybaum, TS Lawrence, MA Morgan.
Cell Cycle. 2011 Dec 15;10(24):4321-9. doi: 10.4161/cc.10.24.18661. Epub 2011 Dec 15.

2010
Poly(ADP-Ribose) Polymerase 1 Modulates the Lethality of CHK1 Inhibitors in Carcinoma Cells.
C Mitchell, M Park, P Eulitt, C Yang, A Yacoub, P Dent.
Mol Pharmacol. 2010 Nov;78(5):909-17. doi: 10.1124/mol.110.067199. Epub 2010 Aug 9.

(This is an incomplete list, last updated AUGUST 2017)

 

Please wait...